Analysts show improved sentiment towards NeuroPace, upgrading their numbers and reducing losses per share. A wide gap in price targets implies a broad range of business scenarios. NeuroPace is expected to outpace industry growth.
NeuroPace's high P/S ratio is justified by expected strong revenue growth, outpacing the Medical Equipment industry. Shareholders are optimistic about future revenues, holding onto their shares.
$ニューロペース インク(NPCE.US)$So the price action on this really looks like the bull run will take it up. It recently ipo'd so theres a ton of volume surging through this. The macd doesnt look to good but it could continue to churn upward. The vortex5 its about to cross the .75 line and would that be the buy signal? Will we see institutional buying at these levels?
ニューロペース インクに関するコメント
• $バンク オブ カリフォルニア(BANC.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $カレン フロスト バンカーズ(CFR.US)$: Raymond James Upgrades to Outperform from Market Perform
• $WW グレインジャー(GWW.US)$: Wolfe Research Upgrades to Outperform from Peerperform
• $インビテーション・ホームズ(INVH.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB バンコープ(PCB.US)$: Raymond James Upgrades to Outperform from Market Perfor...
It recently ipo'd so theres a ton of volume surging through this.
The macd doesnt look to good but it could continue to churn upward.
The vortex5 its about to cross the .75 line and would that be the buy signal?
Will we see institutional buying at these levels?
IPO’ed today
まだコメントはありません